look news india
Hester Biosciences Ltd: Hester Biosciences Ltd, India's leading animal health company that manufactures vaccines and healthcare products, reported a consolidated net profit of Rs 8.39 crore for the second quarter of fiscal 2025 ending September 2024, compared to a net profit of Rs 4.04 crore. Had happened. There has been an increase of 108 percent in the second quarter of financial year 2024.
The company reported revenue from operations of Rs 83.69 crore in Q2FY25, up 19 per cent year-on-year from revenue of Rs 70.46 crore in Q2FY24. Ebitda for Q2FY25 ended September 2025 was Rs 21.96 crore, up 15 per cent year-on-year from Ebitda of Rs 19.12 crore for Q2FY24. EPS per share for Q2FY25 at Rs. Was 9.86.
The company focuses on diversifying its product portfolio by introducing new, innovative solutions across all sectors. Along with this the company is continuously enhancing our operational efficiency leading to profitability and growth. The company's mission is to establish Hester as a comprehensive animal health company that meets the growing needs of the industry through a broad range of products and services.
The subsidiary in Nepal had completed export orders from government tenders and demonstrated its growth potential by meeting the local demand for vaccines. Hester Nepal has become debt free with strong cash flow quarter after quarter. Hester Africa is actively participating in international tenders and meeting business demands with the increasing awareness and demand for vaccines in various African countries.
The company reported a net profit of Rs 15.88 crore for H1FY2025 ending September 2024, up 48 per cent from net profit of Rs 10.75 crore for H1FY2024.
In H1FY25, the company reported revenue from operations at Rs 165.90 crore, up 5 per cent year-on-year. Ebitda for H1FY2025 ending September 2024 was Rs 41.69 crore, showing a year-on-year growth of 16 per cent from EBITDA of Rs 36 crore in H1FY2024. EPS for H1FY25 stood at Rs 18.66 per share.